The influence of dietary supplementation with the leucine metabolite β -hydroxy- β -methylbutyrate (HMB) on chemotaxis, phagocytosis and respiratory burst of peripheral blood granulocytes and monocytes in calves

Roman Wójcik (✉ brandy@uwm.edu.pl)

University of Warmia and Mazury in Olsztyn <https://orcid.org/0000-0002-7405-6328>

Joanna Małaczewska

Uniwersytet Warmińsko-Mazurski Wydział Medycyny Weterynaryjnej

Grzegorz Zwierzchowski

Uniwersytet Warmińsko-Mazurski Wydział Biologii i Biotechnologii

Jan Miciński

Uniwersytet Warmińsko-Mazurski Wydział Bioinżynierii Żwierząt

Edyta Kaczorek-Łukowska

Uniwersytet Warmińsko-Mazurski Wydział Medycyny Weterynaryjnej

Research article

Keywords: β -hydroxy- β -methylbutyrate, granulocytes, monocytes, chemotaxis, phagocytosis, respiratory burst calves

Posted Date: February 20th, 2020

DOI: <https://doi.org/10.21203/rs.2.20386/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Veterinary Research on June 1st, 2020. See the published version at <https://doi.org/10.1186/s12917-020-02389-1>.

Abstract

Background The objective of this study was to evaluate the effect of HMB on the chemotactic activity, phagocytic activity and respiratory burst of peripheral blood granulocytes and monocytes in calves.

Method The experiment was performed on 14 calves aged 30 ± 2 days, divided into two equal groups of control (group I) and experimental (group II) animals. The feed administered to experimental group calves was supplemented with HMB (Metabolic Technologies Inc. Ames, IA, USA) at 40 mg/kg BW, whereas control calves were administered standard farm-made feed without supplementation. Blood was sampled from the jugular vein immediately before the experiment (day 0) and on experimental days 15, 30 and 60 to determine: chemotactic activity (MIGRATEST® kit), phagocytic activity (PHAGOTEST® kit) and respiratory burst (BURSTTEST® kit) of peripheral blood granulocytes and monocytes by flow cytometry.

Results An analysis of granulocyte and monocyte chemotactic activity and phagocytic activity revealed significantly higher levels of phagocytic activity in calves administered HMB than in the control group, expressed in terms of the percentage of phagocytising cells and mean fluorescence intensity (MFI). HMB also had a positive effect on the oxidative metabolism of both granulocytes and monocytes after stimulation with *Escherichia coli* bacteria and with PMA (4-phorbol-12- β -myristate-13-acetate), expressed in terms of the percentage of oxidative metabolism and MFI.

Conclusion HMB stimulates non-specific cell-mediated immunity, which is a very important consideration in newborn calves that are exposed to adverse environmental factors in the first weeks of their life. The supplementation of animal diets with HMB for both preventive and therapeutic purposes can also reduce the use of antibiotics in animal production.

Background

Considerable research has been done into preparations that simulate immune mechanisms, in particular non-specific cell-mediated and humoral immunity, in the youngest animals [1,2,3,4,5]. A healthy immune system plays a particularly important role in newborns, including in calves that are far more susceptible to infections (viral, bacterial and other) than adult individuals [6,7,8].

Non-infectious factors, such as the season of birth, low birth weight, unfavorable environment, absence of colostrum feeding after birth or colostrum feeding at an inappropriate time, as well as infectious factors that cause gastrointestinal and respiratory diseases, are the most frequent causes of disease that contribute to high mortality in newborn calves and cause production losses [6,7,8,9,10,11,12,13,14,15]. These diseases are difficult to treat and the prognosis is doubtful, which is why prevention, including immunoprevention, could play a very important role in calf rearing [16,17,18]. The search for effective immunostimulants, in particular feed additives, continues, and β -hydroxy- β -methylbutyrate (HMB) could be one of such supplements.

Beta-hydroxy- β -methylbutyrate occurs naturally in humans, animals and plants. This endogenous metabolite of the branched-chain amino acid (BCAA) leucine (LEU) is produced when leucine is oxidised in the cell cytoplasm, mainly in the liver and muscles. Nearly 80% of endogenous LEU is used in protein synthesis, and the remainder is transformed into α -ketoisocaproate (α -KIC) which can undergo further conversion in two processes. The first process occurs in the mitochondria where α -KIC is oxidised to isovaleryl-CoA by branched-chain ketoacid dehydrogenase (BCKAD). 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) is synthesised after several steps. An alternative process takes place in the cytosol where HMB is produced from α -KIC by the KIC dioxygenase enzyme. Under normal conditions, approximately 5% of leucine is metabolised into HMB, whereas KIC is mostly converted to isovaleryl-CoA [19,20].

Small quantities of HMB are found in alfalfa, corn (corn silage), milk, cheese, citrus fruit (grapefruit), selected fish species (catfish), red wine and red meat. The quantity of HMB that occurs naturally in the body and is supplied with food is insufficient and, therefore, has to be supplemented from external sources [21,22,23]. HMB is a safe compound that does not produce side effects even if administered at excessive doses, and excess HMB is excreted with urine [24].

According to research studies conducted on several animal species: pigs [25,26,27], cattle [28,29], goats [30], chickens [31], geese [32] and fish [33,34] HMB can stimulate immune mechanisms. However, little is known about its exact mechanism of action and effects on different immunity parameters in animals, including calves. Therefore, the aim of this study was to evaluate the effect of dietary supplementation with HMB on the chemotaxis, phagocytosis and respiratory burst of peripheral blood granulocytes and monocytes in calves. The present study complements our previous research into the influence of HMB on selected parameters of non-specific cell-mediated [28] and humoral immunity [29] in calves.

Results

The chemotactic activity of peripheral blood neutrophils in calves was expressed by the chemotactic index (Figure 3, Figure 4). On experimental days 30 and 60, the mean values of the chemotactic index increased significantly ($p < 0.001$ and $p < 0.01$, respectively) in the group of calves whose diets were supplemented with HMB (experimental group) in comparison with the non-supplemented animals (control group). In the experimental group, the mean value of the chemotactic index also increased significantly ($p < 0.001$) on experimental days 30 and 60 relative to its mean baseline value (day 0).

The analysis of the phagocytic activity of peripheral blood neutrophils revealed that the mean percentage of phagocytising neutrophils was significantly higher ($p < 0.05$ or $p < 0.01$) (Figure 5, Figure 6) in the experimental group than in the control group throughout the entire experiment. In the experimental group, the mean percentage of phagocytising neutrophils increased significantly ($p < 0.05$) on days 30 and 60 relative to the mean baseline value of this parameter on day 0. The MFI of granulocytes, which denotes the number of bacteria ingested per phagocyte (Figure 7), increased significantly ($p < 0.001$, $p < 0.01$

respectively) between experimental days 15 and 30 in the experimental group relative to the control group and relative to the mean baseline value (day 0).

The phagocytic activity of peripheral blood monocytes, expressed as the mean percentage of phagocytising monocytes (Figure 8, Figure 9), on experimental days 30 and 60 increased significantly ($p < 0.0001$, $p < 0.001$ respectively) in the experimental group relative to the control group and relative to the mean baseline value (day 0). Similarly to neutrophils, the MFI of monocytes, which denotes the number of bacteria ingested per phagocyte (Figure 10), increased significantly ($p < 0.0001$, $p < 0.001$ respectively) between experimental days 15 and 30 in the experimental group relative to the control group and relative to the mean baseline value (day 0).

The respiratory burst activity (metabolism of highly reactive oxygen species) of peripheral blood neutrophils increased in the experimental group fed HMB-supplemented diets relative to the control group and relative to the mean baseline value (day 0) throughout the entire experiment. An increase was observed in the mean percentage of cells stimulated to undergo respiratory burst (Figure 11, Figure 12) and in the MFI of neutrophils denoting the respiratory burst activity of different neutrophils (Figure 13). However, a significant ($p < 0.05$ or $p < 0.01$ or $p < 0.001$ or $p < 0.0001$) increase in the mean values of the above parameters was observed only after stimulation with potent respiratory burst activators, PMA and *E. coli* bacteria, throughout the entire experiment. The stimulation with N-formyl-methionyl-leucyl-phenylalanine (fMLP), a weak activator of respiratory burst, did not induce significant differences in the mean percentage of cells stimulated to undergo respiratory burst or the MFI of neutrophils between the control group and the experimental group or relative to the mean baseline values (day 0) (Figure 11).

Similarly to granulocytes, the stimulation of peripheral blood monocytes with *E. coli*, PMA and fMLP significantly ($p < 0.05$ or $p < 0.01$ or $p < 0.001$) increased the mean percentage of cells stimulated to undergo respiratory burst (Figure 14, Figure 15) and the mean intensity of respiratory burst in monocytes (Figure 16) in the experimental group relative to the control group and relative to mean baseline values (day 0).

Discussion

This study evaluated the effect of the supplementation of calf diets with HMB, a natural metabolite of leucine, on different stages of phagocytosis: chemotaxis and intracellular ingestion and killing of bacteria by peripheral blood granulocytes and monocytes.

There is considerable evidence to indicate that HMB stimulates non-specific immune mechanisms, including phagocytosis, in many animal species: pigs [35], chicken [31,36], geese [32] and fish [34,37,38] however, these effects have been rarely investigated in calves [28]. HMB is a strong anticatabolic agent and a regulator of protein metabolism, and it is widely used in sports and bodybuilding to increase strength, muscle mass and exercise performance [39,40,41,42,43]. Immune health is also highly correlated with protein synthesis because mounting immune responses require the generation of new

cells and the synthesis of antigen-presenting machinery, immunoglobulins, cytokines, cytokine receptors and acute phase proteins.

In the present study, the observed increase in the chemotactic activity of peripheral blood neutrophils, expressed as the chemotactic index as the most accurate parameter for assessing chemotactic activity [44], in the group of experimental calves supplemented with HMB relative to control group calves cannot be compared with published data because such experiments have not been conducted in calves or in other animal species. As mentioned previously, numerous authors [28,31,32,34,35,36,37,38] have reported on the positive effects of HMB on phagocytosis in several animal species, but the supplement's impact on specific stages of phagocytosis has never been described.

The significant increase in the phagocytic activity of monocytes and granulocytes in the experimental group relative to the control group was reflected by an increase in the percentage of phagocytising cells as well as an increase in the mean number of bacteria ingested per phagocyte, expressed as MFI. Similar results were noted in our previous studies of geese [32] and goats [45]. In a study by Siwicki et al. [37], the potential killing activity (PKA) of granulocytes and monocytes increased by 140% in fish (rainbow trout and carp) stimulated with various doses of HMB relative to the control group. The analysed supplement exerted the most stimulatory effect on PKA when administered at doses higher than 50 mg HMB/mL. A study of rainbow trout [38] fed pellets with various HMB content (0, 10, 25 or 50 mg/kg BW/day) for 8 weeks confirmed that HMB stimulates the activity of phagocytes (100 % increase in PKA) relative to the control group. Similar results were reported by Siwicki et al. [46] who examined the effect of two HMB doses (50 and 100 mg HMB/kg BW/day) administered over a period of 4 weeks on non-specific cell-mediated immunity in the common carp (*Cyprinus carpio*). The PKA of pronephric phagocytes was significantly higher ($p < 0.05$) in HMB-fed carp than in the control group. However, significant differences were not observed between experimental carp administered HMB doses of 50 and 100 mg/kg BW/day.

In the current study, HMB also significantly enhanced the intracellular killing activity of granulocytes and monocytes stimulated with strong mitogens (PMA and *E. coli* bacteria), which was expressed by an increase in the percentage of cells stimulated to undergo respiratory burst and in MFI in these cells. Higher values of the above parameters indicate that pathogens were more effectively eliminated from the body by phagocytising cells. Similar results were reported by Siwicki et al. [38], where a spectrophotometric analysis in the respiratory burst activity test revealed that the production of highly reactive oxygen species by head kidney phagocytes doubled in rainbow trout whose diets were supplemented with HMB for 8 weeks. In a study of rainbow trout (*Oncorhynchus mykiss*) and carp (*Cyprinus carpio*) [40], the addition of > 50 mg/ml HMB to the culture medium increased respiratory burst activity by up to 84% ($p < 0.01$) in pronephric phagocytes grown in a culture medium (RPMI-1640) containing 0, 0.1, 1, 5, 10, 25, 50 or 100 mg HMB/mL relative to the cells cultured without HMB. In an *in vitro* study, Peterson et al. [36] evaluated macrophages that were isolated from a chicken macrophage cell line (MQ-NCSU) and cultured in the presence of 20, 40 and 80 µg of HMB. Supernatant fractions were also tested for the presence of nitrite. The phagocytic potential of MQ-NCSU macrophages exposed to 40

µg of HMB was significantly higher (31.7%) relative to the controls. Sephadex-elicited macrophages treated with 80 µg HMB exhibited a 14.4 % increase in phagocytosis compared with controls.

The mechanism by which HMB influences phagocytising cells and other immunocompetent cells, isolated in this experiment, has not yet been fully elucidated. It can be hypothesised that as a leucine catabolite, HMB is an abundant source of energy for biological activities [19] or that it is an effector of energy metabolism.

The results of this study suggest that HMB is a highly effective dietary supplement that stimulates immunity animals. HMB stimulates non-specific cell-mediated immunity, which is a very important consideration in newborn calves that are exposed to adverse environmental factors in the first weeks of their life. The supplementation of animal diets with HMB for both preventive and therapeutic purposes can also reduce the use of antibiotics in animal production.

Conclusions

This study demonstrated significantly higher levels of granulocyte chemotactic activity (expressed by the chemotactic index) and phagocytic activity (expressed by the percentage of phagocytes), a significantly higher average number of bacteria eliminated by one phagocyte (expressed by the average fluorescence intensity of monocytes and granulocytes), and significantly higher intracellular killing activity of granulocytes and monocytes stimulated with PMA and *E. coli* (expressed by the percentage of stimulated cells and average fluorescence intensity) in experimental calves administered HMB than in control group animals whose diets were not supplemented.

Methods

Experimental design

The experiment was performed on 14 Polish Holstein-Friesian calves originating from a private dairy herd located in the north-eastern region of Poland. The calves (aged 30±2 days) were fed colostrum within 1 hour after birth. Colostrum was administered in the amount of 2 kg/animal/day for 5 days. After that period, the animals were fed milk replacers until the age of 8 weeks. Immediately after birth, the calves were moved to wooden sheds outside the cow barn. At the age of one month, calves were included in a 60-day study. Prior to the experiment, the animals were weighed and divided into two groups by the analogue method. The control group (I) comprised calves fed a standard farm-made diet. Between the age of 5 days to 8 weeks, they were fed the Mlekowit (Polmass, Bydgoszcz, Poland) milk replacer in the amount of 4 L/day/animal in two portions. In the experimental group (II), the same quantity of the milk replacer was supplemented with β-hydroxy-β-methylbutyrate (HMB, Metabolic Technologies Inc. Ames, IA, USA) at 40 mg/kg BW. Beginning from the first week, the animals had unlimited access to solid feed (maize silage, meadow hay and Jösera Kälberkost prestarer) which was supplied in increasing quantities.

Fresh water was supplied ad libitum. All calves enrolled in to the study survived the experimental period and were still breed in the herd.

Sample collection

Blood was sampled from the jugular vein prior to HMB supplementation of feed and on days 15, 30 and 60 of the experiment to determine and compare: chemotactic activity (MIGRATEST® kit) (Glycotope Biotechnology GmbH, Heidelberg, Germany), phagocytic activity (PHAGOTEST® kit) (Orpegen Pharma, Heidelberg, Germany) and respiratory burst (BURSTTEST® kit) (Orpegen Pharma, Heidelberg, Germany) of peripheral blood granulocytes and monocytes by flow cytometry.

Determination of the chemotactic activity of blood granulocytes and monocytes in calves with the MIGRATEST® kit

The chemotactic activity of blood granulocytes and monocytes was determined with the MIGRATEST® kit (Orpegen Pharma, Heidelberg, Germany) based on the attached instructions. The assay involved leucocyte-rich plasma (LRP) that was isolated from heparinised whole blood by spontaneous sedimentation. The LRP was extracted from each sample, and it was transferred to two cell culture inserts with pore size of 3.0 µm. One insert was placed in a well containing N-formyl-methionyl-leucyl-phenylalanine (fMLP) (Glycotope Biotechnology GmbH, Heidelberg, Germany) as the chemoattractant. The other insert was used as negative control, and it was placed in a buffer solution that did not contain the chemotactic peptide. Chemotaxis was quantified over a period of 30 min at a temperature of 37°C. An antibody reagent (FITC-labelled anti-CD62L (Glycotope Biotechnology GmbH, Heidelberg, Germany) containing counting beads was applied for 10 minutes to stain the cells. The samples were placed on ice, and vital DNA dye (Glycotope Biotechnology GmbH, Heidelberg, Germany) was added for 5 min before flow cytometry. The number of migrated neutrophils and L-selectin shedding from the surface of activated cells were determined by flow cytometry. The results were expressed by the chemotactic index which was calculated by dividing the number of cells migrating towards fMLP by the number of migrating cells in the absence of fMLP [47].

Determination of the phagocytic activity of blood granulocytes and monocytes in calves with the PHAGOTEST® kit

The phagocytic activity of blood granulocytes and monocytes was evaluated with the use of the PHAGOTEST® kit (Orpegen Pharma, Heidelberg, Germany) in line with the attached instructions. The manufacturer's specifications were also observed in the process of preparing the reagents. The negative control was a 5 mL test tube (blue, Beckman Coulter, Fullerton, CA, USA) filled with 100 µL of whole heparinised blood chilled to 0°C. The experimental test tube (5 mL, blue, Beckman Coulter, Fullerton, CA, USA) contained 20 µL of chilled *E. coli* bacteria (Orpegen Pharma, Heidelberg, Germany). Both tubes were shaken at low speed for around 3 seconds. The experimental test tube was incubated at 37°C for 10 minutes. The negative control was incubated at 0°C on ice. The incubated samples were combined with 100 µL of the quenching solution (Orpegen Pharma, Heidelberg, Germany), and the test tubes were

shaken. The washing solution (Orpegen Pharma, Heidelberg, Germany) chilled to 0°C was added in the amount of 3 ml. Both samples were centrifuged for 5 min at 4°C (250 x g), and the supernatant was removed. The samples were rinsed twice, after which, 2 ml of the lysing solution (Orpegen Pharma, Heidelberg, Germany) with room temperature was added to each sample. The samples were shaken, incubated at room temperature for 20 min, and centrifuged for 5 min at 4°C (250 x g). The supernatant was removed. Each sample was combined with 3 mL of the washing solution (Orpegen Pharma, Heidelberg, Germany) with a temperature of 0°C. The samples were centrifuged for 5 min at 4°C (250 x g), and the supernatant was removed. A DNA staining solution (Orpegen Pharma, Heidelberg, Germany) chilled to 0°C was added in the amount of 200 µL. The samples were shaken and incubated on ice for 10 min. The phagocytic activity of the evaluated cells was measured in a cytometer (Beckmann Coulter, Epics XL, USA) within less than 60 min after the addition of the last reagent. The Phagotest kit (Orpegen Pharma, Heidelberg, Germany) contains fluorescein (FITC)-stained *E. coli* bacteria which are phagocytised by macrophages. Cell nuclei are also stained. The number of phagocytising cells, granulocytes and monocytes are determined separately. Phagocytic activity is evaluated based on the mean fluorescence intensity (MFI) of individual cells that ingest bacteria.

Determination of the oxidative metabolism of blood granulocytes and monocytes in calves with the BURSTTEST® Kit

The oxidative metabolism of blood granulocytes and monocytes was determined with the BURSTTEST (Orpegen Pharma, Heidelberg, Germany) based on the attached instructions. The manufacturer's specifications were also observed in the process of preparing the reagents. Whole heparinised blood was split into four portions and placed in four 100 µL test tubes (blue, Beckman Coulter, Fullerton, CA, USA) chilled to 0°C. The first sample (experimental) was combined with 20 µL of chilled *E. coli* bacteria (Orpegen Pharma, Heidelberg, Germany); the second sample (negative control) was combined with 20 µL of the washing solution (Orpegen Pharma, Heidelberg, Germany); the third sample (low control) was combined with 20 µL of fMLP (N-formyl-methionyl-leucyl-phenylalanine) (Orpegen Pharma, Heidelberg, Germany); the fourth sample (high control) was combined with 20 µL of PMA (4-phorbol-12-β-myristate-13-acetate) (Orpegen Pharma, Heidelberg, Germany). The contents of each test tube were stirred and incubated at 37°C for 10 min, excluding the sample containing fMLP which was incubated for 7 min. Twenty µL of substrate solution (Orpegen Pharma, Heidelberg, Germany) was added to each incubated sample, and the tubes were thoroughly shaken. The samples were incubated at 37°C for 10 min, and 2 mL of the lysing solution (Orpegen Pharma, Heidelberg, Germany) at room temperature was added to each test tube. The samples were shaken and incubated at room temperature for 20 min. The test tubes were centrifuged at 4°C for 5 min (250× g), and the supernatant was removed. The samples were rinsed once with 3 ml of the washing solution (Orpegen Pharma, Heidelberg, Germany), they were centrifuged at 4°C for 5 min (250× g), and the supernatant was removed. Each sample was combined with 200 µL of the staining solution chilled to 0°C, it was shaken and incubated for 10 min on ice. The intracellular killing activity of phagocytes was measured in a cytometer (BD Biosciences, San Jose, California, USA) within less than 30 min after the addition of the last reagent. The cells were stimulated with three activators: *E. coli* bacteria (Orpegen Pharma, Heidelberg, Germany), PMA (Orpegen

Pharma, Heidelberg, Germany) as the strong activator, and fMLP (Orpegen Pharma, Heidelberg, Germany) as the weak activator. Oxidative stress was induced with H₂O₂, and mitochondria-generated reactive oxygen species converted dihydrorodamine (123-DHR) to cation rhodamine 123 (R123), the fluorescence emitter.

FACS Acquisition and Analysis

Flow cytometry was performed with the FACSCanto II cytometer (BD Biosciences, San Jose, California, USA). Data were acquired with FACSDiva version 6.1.3 software (BD Biosciences, San Jose, California, USA) and analysed in FlowJo 10 software (Tree Star, Ashland, Oregon, USA). The cytometry setup and tracking beads (CST; BD Biosciences, San Jose, California, USA) were used to initialise the photomultiplier tube (PMT). Unstained control cells and a single stain control for every fluorochrome were prepared and used to establish flow cytometric compensation. Granulocytes and monocytes were gated based on forward and side scatter (FSC/SSC) parameters (Figure 1).

Granulocytes and counting beads were identified in PerCP to SSC scatter and depicted in FSC to SSC scatter. Data acquisition ended after the acquisition of exactly 2000 events in the region of counting beads. The number of events in the region of granulocytes was counted, and the number of granulocytes in the control sample was compared with the number of granulocytes in the positive control sample after stimulation with fMLP. The decrease in L-selectin expression can be measured simultaneously. Downregulation of this cell adhesion molecule correlates directly with the activation of neutrophils under exposure to chemotactic factors. Changes in cell shape precede cell migration and can be measured by analysing changes in forward scatter signals during flow cytometry (Figure 2).

Statistical Analysis

Numerical results were presented as the arithmetic mean $\pm$ SD. The obtained results were processed statistically by two-way ANOVA for orthogonal design. In post-hoc analysis, Dunnett's test was used to compare day 0 with days 15, 30, and 60 in group II (significance of differences between days: (A) $p < 0.05$; (B) $p < 0.01$; (C) $p < 0.001$; (D) $p < 0.0001$), and Tukey's test for equal groups to compare group II with group I at each time point (significance of differences between groups: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$) with the use of GraphPad Prism 7 software. The significance level has been set to 5% HMB.

List Of Abbreviations

BCAA - branched-chain amino acid

BW - body weight

CD - cluster of differentiation

CR3 - complement receptor 3

fMLP - N-formyl-methionyl-leucyl-phenylalanine

GC-SF - granulocyte colony-stimulating factor

HMB - β -hydroxy- β -methylbutyrate

HMB-FA - β -hydroxy- β -methylbutyrate free acid

HMG-CoA - 3-hydroxy-3-methylglutaryl-coenzyme A

IFN- γ – interferon- γ

IL - interleukin

LEU – leucine

MFI - mean fluorescence intensity

PKA - potential killing activity

PMA - 4-phorbol-12- β -myristate-13-acetate

SR-A - class A scavenger receptors

TNFR1 - TNF- α receptor 1

TNF- α - tumour necrosis factor α

α -KIC - α -ketoisocaproate

Declarations

Ethics approval and consent to participate

Animal experiments were carried out in conformance with the Animal Protection Law (Journal of Laws of 24 February 2005, No. 33, item 289) and upon the recommendations of the Animal Ethics Committee of the University of Warmia and Mazury in Olsztyn. This study was conducted upon the approval of the local Ethics Committee (decision no. 18/2013/N). The herd owner gave written informed consent to use the animals in the study.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

"Project financially co-supported by Minister of Science and Higher Education in the range of the program entitled "Regional Initiative of Excellence" for the years 2019-2022, Project No. 010/RID/2018/19, amount of funding 12.000.000 PLN."

Authors' contributions

RW: conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing—original draft preparation, writing-review and editing, visualization, supervision, project administration, funding acquisition;

JMa: conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing—original draft preparation, writing-review and editing;

GZ: conceptualization, validation, investigation, resources, writing-review and editing, supervision;

JMi: conceptualization, validation, investigation, writing-review and editing, funding acquisition;

EK-Ł: investigation, writing-review and editing, visualization;

All authors have read and approved the manuscript.

Acknowledgements

Not applicable

References

1. Wójcik R, Milewski S, Małaczewska J, Tański Z, Brzostowski H, Siwicki AK. Defence mechanisms of the offspring of ewes fed a diet supplemented with yeast (*Saccharomyces cerevisiae*) during pregnancy and lactation. *Centr Eur J Immunol* 2008;33:197-201.
2. Milewski S, Sobiech P, Bednarek D, Wójcik R, Małaczewska J, Zaleska B, Siwicki AK. Effect of oligosaccharides supplementation on the meat performance traits and selected indicators of humoral immunity in lambs. *Bull Vet Inst Pulawy* 2010;54:175-9.
3. Wójcik R. Effect of brewer's yeast (*Saccharomyces cerevisiae*) extract on selected parameters of humoral and cellular immunity in lambs. *Bull Vet Inst Pulawy* 2010;54:181-7.

4. Ząbek K, Milewski S, Wójcik R, Siwicki AK. Effect of β -1,3/1,6-D-glucan in diet on productivity and humoral and cellular defense mechanisms in sheep. *Acta Vet Brno* 2013;82:141-6.
5. Wójcik R. The effect of Leiber Beta-S on the selected parameters of immunity in calves. *Acta Vet Brno* 2014;83:113-8.
6. Godden S. Colostrum management for dairy calves. *Vet Clin North Am Food Anim Pract* 2008;24:19-39.
7. Lora I, Gottardo F, Contiero B, Dall'Ava B, Bonfanti L, Stefani A, Barberio A. Association between passive immunity and health status of dairy calves under 30 days of age. *Prev Vet Med* 2018;152:12-5.
8. Cooke RF. Effects on animal health and immune function. *Vet Clin North Am Food Anim Pract* 2019;35:331-41.
9. McGuirk SM. Disease management of dairy calves and heifers. *Vet Clin North Am Food Anim Pract* 2008;24:139-53.
10. Mee JF. Newborn dairy calf management. *Vet Clin North Am Food Anim Pract* 2008;24:1-17.
11. Uetake K. Newborn calf welfare: a review focusing on mortality rates. *Anim Sci J* 2013;84:101-5.
12. Reiten M, Rousing T, Thomsen PT, Otten ND, Forkman B, Houe H, Sørensen JT, Kirchner MK. Mortality, diarrhea and respiratory disease in Danish dairy heifer calves: Effect of production system and season. *Prev Vet Med* 2018;155:21-6.
13. Windeyer MC, Leslie KE, Godden SM, Hodgins DC, Lissemore KD, LeBlanc SJ. Factors associated with morbidity, mortality, and growth of dairy heifer calves up to 3 months of age. *Prev Vet Med* 2014;113:231-40.
14. Svensson C, Hultgren J, Oltenacu PA. Morbidity in 3-7-month-old dairy calves in south-western Sweden, and risk factors for diarrhea and respiratory disease. *Prev Vet Med* 2006;74:162-79.
15. Roberts GL. Fusobacterial infections: an underestimated threat. *Br J Biomed Sci* 2000;57:156-62.
16. Garcia M, Shin JH, Schlaefli A, Greco LF, Maunsell FP, Thatcher WW, Santos JE, Staples CR. Increasing intake of essential fatty acids from milk replacer benefits performance, immune responses, and health of preweaned Holstein calves. *J Dairy Sci* 2015;98:458-77.
17. Hernández-Castellano LE, Özçelik R, Hernandez LL, Bruckmaier RM. Short communication: Supplementation of colostrum and milk with 5-hydroxy-L-tryptophan affects immune factors but not growth performance in newborn calves. *J Dairy Sci* 2018;101:794-800.
18. Flaga J, Korytkowski Ł, Górka P, Kowalski ZM. The effect of docosahexaenoic acid-rich algae supplementation in milk replacer on performance and selected immune system functions in calves. *J Dairy Sci* 2019;102: 8862-73.
19. Nissen SL, Abumrad NN. Nutritional role of the leucine metabolite β -hydroxy- β -methylbutyrate (HMB). *J Nutr Biochem* 1997;8:1–12.
20. Van Koeveering M, Nissen S. Oxidation of leucine and alpha-ketoisocaproate to beta-hydroxy-beta methylbutyrate *in vivo*. *Am J Physiol* 1992;262:E27–E31.

21. Szcześniak KA, Ostaszewski P, Fuller JC Jr, Ciecierska A, Sadkowski T. Dietary supplementation of β -hydroxy- β -methylbutyrate in animals - a review. *J Anim Physiol Anim Nutr (Berl)* 2015;99:405-17.
22. Tatara R. Neonatal programming of skeletal development in sheep is mediated by somatotrophic axis function. *Exp Physiol* 2008;93:763-Q72.
23. Qiao X, Zhang HJ, Wu SG, Yue HY, Zuo JJ, Feng DY, Qi GH. Effect of β -hydroxy- β -methylbutyrate calcium on growth, blood parameters, and carcass qualities of broiler chickens. *Poult Sci* 2013;92:753-9.
24. Vukovich MD, Slater G, Macchi MB, Turner MJ, Fallon K, Boston T, Rathmacher J. Beta-hydroxy-beta-methylbutyrate (HMB) kinetics and the influence of glucose ingestion in humans. *J Nutr Biochem* 2001;12:631-9.
25. Gatnau R, Zimmerman DR, Nissen SL, Wannemuehler M, Ewan RC. Effects of excess dietary leucine and leucine catabolites on growth and immune responses in weanling pigs. *J Anim Sci* 1995;73:159–65.
26. Krakowski L, Krzyżanowski J, Wrona Z, Kostro K, Siwicki AK. The influence of nonspecific immunostimulation of pregnant sows on the immunological value of colostrums. *Vet Immunol Immunopath* 2002;87:89-95.
27. Flummer C, Theil PK. Effect of β -hydroxy β -methyl butyrate supplementation of sows in late gestation and lactation on sow production of colostrum and milk and piglet performance. *J Anim Sci* 2012;90:372–4.
28. Wójcik R, Małaczewska J, Siwicki AK, Miciński J, Zwierzchowski G. The effect of β -hydroxy- β -methylbutyrate (HMB) on the proliferative response of blood lymphocytes and the phagocytic activity of blood monocytes and granulocytes in calves. *Pol J Vet Sci* 2013;16:567-9.
29. Wójcik R, Małaczewska J, Siwicki AK, Miciński J, Zwierzchowski G. The effect of β -hydroxy- β -methylbutyrate (HMB) on selected parameters of humoral immunity in calves. *Pol J Vet Sci* 2014;17:357-9.
30. Ząbek K, Wójcik R, Milewski S, Małaczewska J, Tański Z, Siwicki AK. Effect of β -hydroxy- β -methylbutyrate acid on meat performance traits and selected indicators of humoral immunity in goats. *Jpn J Vet Res* 2016;64:247-56.
31. Peterson AL, Qureshi MA, Ferket PR, Fuller JC Jr. Enhancement of cellular and humoral immunity in young broilers by the dietary supplementation of beta-hydroxy-beta-methylbutyrate. *Immunopharmacol Immunotoxicol* 1999;21:307–30.
32. Puchajda-Skowrońska H, Siwicki AK, Wójcik R, Pudyszak K. Effects of 3-hydroxy-3-methylbutyrate (HMB) on selected performance indices and non-specific defence mechanisms in geese. *Med Weter* 2006;62:89-92.
33. Siwicki AK, Fuller JC Jr, Nissen S, Morand M, Pozet F, Vincent F, Kazuń B. Effect of HMB (β -hydroxy- β -methylbutyrate) on *in vitro* proliferative responses of sheatfish (*Silurus glanis*) and catfish (*Ictalurus melas*) lymphocytes stimulated by mitogens. *Acta Vet Brno* 2004;73:119–22.

34. Siwicki AK, Zakęś Z, Fuller JC Jr, Nissen S, Kazuń K, Głąbski E. The influence of β -hydroxy- β -methylbutyrate (HMB) on cell-mediated immunity in tench *Tinca tinca* (L.): *in vitro* and *in vivo* study. *Aquacult Int* 2006;14:153–61.
35. Ostaszewski P, Kozłowska E, Siwicki AK, Krzyzanowski J, Fuller JC Jr, Nissen S. The immunomodulating activity of dietary β -hydroxy- β -methylbutyrate (HMB) in weanling pigs. *J Anim Sci* 1998;76(Suppl.1):136.
36. Peterson A, Qureshi M, Ferket P, Fuller Jr J. *In vitro* exposure with β -hydroxy- β -methylbutyrate enhances chicken macrophage growth and function. *Vet Immunol Immunopathol* 1999;67:67-78.
37. Siwicki AK, Fuller JC Jr, Nissen S, Ostaszewski P, Studnicka M. *In vitro* effects of beta-hydroxy-beta-methylbutyrate (HMB) on cell-mediated immunity in fish. *Vet Immunol Immunopathol* 2000;76:191-7.
38. Siwicki AK, Morand M, Fuller JC Jr, Nissen S, Goryczko K, Ostaszewski P, Kazuń K, Głombski E. Influence of feeding the leucine metabolite β -hydroxy- β -methylbutyrate (HMB) on the non-specific cellular and humoral defence mechanisms of rainbow trout (*Oncorhynchus mykiss*). *J Appl Ichthyol* 2003;19:44-8.
39. Ostaszewski P, Kostiuk S, Balasinska B, Jank M, Papet I, Glomot F. The leucine metabolite 3-hydroxy-3-methylbutyrate (HMB) modifies protein turnover in muscles of laboratory rats and domestic chickens *in vitro*. *J Anim Physiol Anim Nutr* 2000;84:1–8.
40. Slater G, Jenkins D, Logan P, Lee H, Vukovich M, Rathmacher JA, Hahn AG. Beta-hydroxy-beta-methylbutyrate (HMB) supplementation does not affect changes in strength or body composition during resistance training in trained men. *Int J Sport Nutr Exerc Metab* 2001;11:384-96.
41. Ransone J, Neighbors K, Lefavi R, Chromiak J. The effect of beta-hydroxy beta-methylbutyrate on muscular strength and body composition in collegiate football players. *J Strength Cond Res* 2003;17:34-39.
42. Thomson JS, Watson PE, Rowlands DS. Effects of nine weeks of beta-hydroxy-beta-methylbutyrate supplementation on strength and body composition in resistance trained men. *J Strength Cond Res* 2009;23:827-35.
43. Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, Loughna P, Churchward-Venne TA, Breen L, Phillips SM, Etheridge T, Rathmacher JA, Smith K, Szewczyk NJ, Atherton PJ. Effects of leucine and its metabolite beta-hydroxy-beta-methylbutyrate on human skeletal muscle protein metabolism. *J Physiol* 2013;591:2911–23.
44. Wójcik R, Małaczewska J, Kaczorek-Łukowska E. The applicability of the Migratest® kit for evaluating the chemotactic activity of peripheral blood neutrophils in goats on the example of animals supplemented with β -hydroxy- β -methylbutyrate (HMB). *Pol. J. Vet. Sci.* 2019;22:725-733. doi.org/10.5601/jelem.2019.24.4.1529.
45. Wójcik R, Ząbek K, Małaczewska J, Milewski S, Kaczorek-Łukowska E. The effects of β -hydroxy- β -methylbutyrate (HMB) on chemotaxis, phagocytosis, and oxidative burst of peripheral blood granulocytes and monocytes in goats. *Animals* 2019;9:1031.

46. Siwicki AK, Głabski E, Kazuń K, Kazuń B, Lepa A, Majewicz-Zbikowska M. Effect of dietary administration of the β -hydroxy- β -methylbutyrate on the innate immunity and protection against motile *Aeromonas septicaemia* in fish. Centr Eur J Immunol 2011;36:135-38.
47. Guilhem A, Malcus C, Clarivet B, Plauchu H, Dupuis-Girod S. Immunological abnormalities associated with hereditary haemorrhagic telangiectasia. J Intern Med 2013;274:351-62.

Figures

Figure 1

A. Gating strategy for flow cytometry data analysis. Granulocytes and monocytes were gated based on forward and side scatter (FSC/SSC) parameters. Each cell subset was analysed for the relative number of phagocytosing cells and cells stimulated for respiratory burst (fMLP, PMA or *E. coli* bacteria). B. Gating strategy for analysing flow cytometry data based on the neutrophil migration assay. Granulocytes and counting beads were identified in PerCP to SSC scatter and depicted in FSC to SSC scatter. (a) – control

without stimulation; (b) – control stimulated with fMLP; (c) – HMB without stimulation; (d) – HMB stimulated with fMLP

Figure 2

A.The chemotactic index was calculated by dividing the number of cells that migrated towards fMLP by the number of cells that migrated in the absence of fMLP. Key: I – control group; II – experimental group; SD - standard deviation; Numerical results were presented as the arithmetic mean ± SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at ** p < 0.01; *** p < 0.001; C refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at C – p < 0.001. B. Representative dot plot cytograms showing the percentage of migrating granulocytes and counting beads on day 30 of the experiment. (a) – control without stimulation; (b) – control

stimulated with fMLP; (c) – HMB without stimulation; (d) – HMB stimulated with fMLP. The number of granulocytes relative to the number of whole cells was determined in each sample as soon as 2000 counting beads were acquired. Stimulation with fMLP increased the number of migrated granulocytes (b), (d) relative to the controls without fMLP (a), (c).

Figure 3

A. Percentage of phagocytising granulocytes in calf groups, as determined in the Phagotest® kit. Key: I – control group; II – experimental group; SD - standard deviation. Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at * $p < 0.05$; ** $p < 0.01$; A refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at A – $p < 0.05$. B. Dot plot cytogram showing the percentage of phagocytising granulocytes in control and experimental calves on experimental day 30. Whole heparinised blood from control and experimental animals was incubated for 10 minutes with FITC-labelled *E. coli* in an ice bath at a temperature of 0°C (negative control) or in a water bath at a temperature of 37°C (control and HMB). The percentages of granulocytes with ingested *E. coli* (FITC) bacteria were gated. C. Mean fluorescence intensity (MFI) of granulocytes in calf groups, as determined in the Phagotest® kit. Key: I – control group; II – experimental group; SD - standard deviation; Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at *** $p < 0.001$; B refer to statistically

significant differences between day "0" and the consecutive sampling days within experimental group at B – $p < 0.01$.

Figure 4

A. Percentage of phagocytising monocytes in calf groups, as determined in the Phagotest® kit. Key: I – control group; II – experimental group; SD - standard deviation. Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at *** $p < 0.001$; **** $p < 0.0001$; D refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at D – $p < 0.0001$. B. Dot plot cytogram showing the percentage of phagocytising monocytes in control and experimental calves on experimental day 30. Whole heparinised blood from control and experimental animals was incubated for 10 minutes with FITC-labelled *E. coli* in an ice bath at the temperature of 0°C (negative control) or in a water bath at the temperature of 37°C (control and HMB). The percentages of monocytes with ingested *E. coli* (FITC) bacteria were gated. C. Mean fluorescence intensity (MFI) of monocytes in calf groups, as determined in the Phagotest® kit. Key: I – control group; II – experimental group; SD - standard deviation. Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at *** $p < 0.001$; **** $p < 0.0001$; D refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at D – $p < 0.0001$.

Figure 5

A. Percentage of granulocytes stimulated to undergo respiratory burst in calf groups after stimulation with fMLP, PMA and *E. coli*, as determined in the Bursttest® kit. Key: I – control group; II – experimental group; SD - standard deviation. Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at * $p < 0.05$; ** $p < 0.01$; A, B refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at A – $p < 0.05$; B – $p < 0.01$. B. Dot plot cytogram showing the percentage of granulocytes stimulated to undergo respiratory burst in control and experimental calves on experimental day 30. Whole heparinised blood from control and experimental animals (control and HMB) was divided into four test tubes. The samples were combined with the washing solution (negative control), *E. coli* bacteria (opsonising activator), PMA (strong activator) or fMLP (weak activator) and incubated with dihydrorhodamine 123 in a water bath at a temperature of 37°C. After incubation, cells were lysed and DNA staining solution was added. The percentages of granulocytes stimulated to undergo respiratory burst (conversion of dihydrorhodamine 123 to rhodamine 123) were gated. C. Mean fluorescence intensity (MFI) of granulocytes in calf groups after stimulation with fMLP, PMA and *E. coli*, as determined in the Bursttest® kit. Key: I – control group; II – experimental group; SD - standard deviation. Numerical results were

presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$; B, C, D refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at B – $p < 0.01$; C – $p < 0.001$; D – $p < 0.0001$.

Figure 6

A. The percentage of monocytes stimulated to undergo respiratory burst in calf groups after stimulation with fMLP, PMA and E. coli, as determined in the Bursttest® kit. Key: I – control group; II – experimental group; SD - standard deviation. Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; B, C refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at B – $p < 0.01$; C – $p < 0.001$. B. Dot plot cytogram showing the percentage of monocytes stimulated to undergo respiratory burst in control and experimental animals on experimental day 30. The percentages of monocytes stimulated to undergo respiratory burst were gated. C. Mean fluorescence intensity (MFI) of monocytes in calf groups after stimulation with fMLP, PMA and E. coli, as determined in the Bursttest® kit. Key: I – control group; II – experimental group; SD - standard deviation;

Numerical results were presented as the arithmetic mean $\pm$ SD. The significance level was set at 0.05. Asterisks refer to statistically significant differences between control and experimental group within the same sampling day at * $p < 0.05$; ** $p < 0.01$; A, B, C refer to statistically significant differences between day "0" and the consecutive sampling days within experimental group at A – $p < 0.05$; B – $p < 0.01$; C – $p < 0.001$.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [NC3RsARRIVEGuidelinesChecklistfillable.pdf](#)